REMISSION IS NOT ASSOCIATED WITH DRD2 Rs1800497 AND DAT1 Rs28363170 GENETIC VARIANTS IN MALE SCHIZOPHRENIC PATIENTS AFTER 6-MONTHS MONOTHERAPY WITH OLANZAPINE

Maja Zivkovic1*, Alma Mihaljevic-Peles12*, Dorotea Muck-Seler3, Marina Sagud12, Lana Ganoci4, Suzana Vlatkovic5, Lucija Tudor3, Nela Pivac3 & Nada Bozina4

1Department of Psychiatry and Psychological Medicine, University Hospital Center Zagreb, Zagreb, Croatia
2School of Medicine, University of Zagreb, Zagreb, Croatia
3Rudjer Boskovic Institute, Zagreb, Croatia
4Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia
5University Psychiatric Hospital Vrapce, Zagreb, Croatia

*Authors contributed equally do this manuscript

SUMMARY

Background: Symptomatic remission is an achievable goal in the treatment of schizophrenia. The type of antipsychotic medication and particular genetic variants of the dopaminergic system might be associated with remission. Potential pharmacogenetic markers of the treatment response to antipsychotic medication are missing. This study assessed the possible association between dopamine receptor type 2 (DRD2 rs1800497) and dopamine transporter (DAT1 rs28363170) gene variants with symptomatic remission in schizophrenia.

Subjects and methods: Olanzapine (5-20 mg/d) monotherapy was administered for 6 months to 150 male Caucasian subjects with schizophrenia. Remission was evaluated according to "Remission in Schizophrenia Working Group" criteria. Genotyping was performed by PCR-RFLP.

Results: Symptomatic remission was found in 31% of patients. DRD2 rs1800497 and DAT1 rs28363170 gene variants were not significantly associated with symptomatic remission. The limitations are a relatively small sample size of patients with schizophrenia (N=150), especially of group with symptomatic remission (N=45). However, the study had moderate but adequate sample sizes for most of the comparisons. Only two dopaminergic polymorphisms were analyzed, and plasma concentration of olanzapine was not determined.

Conclusion: These results revealed a lack of association between DRD2 rs1800497 and DAT1 rs28363170 genetic variants and symptomatic remission in male patients treated with olanzapine, suggesting that these genetic variants could not be used to predict symptomatic remission to olanzapine monotherapy. Negative results should be further confirmed or rejected in the larger samples, including haplotype analyses, to detect clinically useful and easy obtainable pharmacogenetic markers that might predict therapeutic response or remission in schizophrenia.

Key words: schizophrenia - olanzapine - symptomatic remission - genetic variants - DRD2 - DAT

INTRODUCTION

Antipsychotic drugs play a key role in the treatment of schizophrenia by blocking the dopaminergic D2 receptor type 2 (DRD2). This is a property shared by all antipsychotics including olanzapine, which is one of the most prescribed second-generation antipsychotic drug (Lally & MacCabe 2015). Besides blockade of DRD2 and serotonin 2A receptors (5-HT2AR), olanzapine shows high affinity for serotonin 2C receptors (5-HT2CR), dopamine D1, D3, D4 receptors, muscarinic receptors M1-5, adrenergic α1-receptor and histamine receptor H1 (Ishigooka et al. 2004). The advantages of olanzapine include its clinical efficacy, its ability to reduce negative symptoms and its low propensity to produce movement disorders (Lieberman et al. 2005). Poor response to treatment is frequent, although novel antipsychotic medications are in use (Lally et al. 2016). Besides the important contribution of the non-genetic factors to the therapeutic response to antipsychotics, genetic variants of the genes coding for various receptors, transporters and enzymes of the dopaminergic system might play an important role in the treatment response, resistance ad remission in patients with schizophrenia (see Lally et al. 2016). However, the literature findings are inconsistent (Yoshida & Müller 2018), since the studies included different medications and different criteria for response or remission. Therefore, this study focused on the two most frequently studied genetic polymorphisms (in the dopaminergic receptors type 2 (DRD2) rs1800497 and dopaminergic transporter (DAT) rs28363170) and remission to olanzapine monotherapy, with aim to elucidate their possible use as easy obtainable pharmacogenetic markers of the remission to olanzapine.
The single nucleotide polymorphism DRD2 Taq1A (rs1800497; 2139C/T) results in a cytosine to thymine change at nucleotide position 2139, leading to the existence of two alleles, A1 and A2. Literature data on the association of this functional polymorphism (Tunbridge et al. 2019) DRD2 rs1800497 with therapeutic response to olanzapine are inconsistent (Mi et al. 2011). Meta-analysis (Zhang et al. 2011) that examined the relationship between DRD2 polymorphisms, including rs1800497, and different antipsychotic response, reported similar response rate between A1 carriers versus A2/A2 genotype, or between A2 allele carriers versus A1/A1 genotype carriers. However, this meta-analysis did not include olanzapine monotherapy (Zhang et al. 2011).

The 40-bp variable-number tandem repeat (VNTR) in the 3’-untranslated region of the dopamine transporter gene (DAT1 or SLC6A3) is a frequently studied polymorphism (DAT1 VNTR, rs28363170) with 2 most common alleles, the 9-repeat (9R) and the 10-repeat (10R). Its functionality has been recently questioned (Tunbridge et al. 2019). A limited number of studies elucidated an association between DAT1 rs28363170 and antipsychotic response, including olanzapine, generally with negative findings (Szekerex et al. 2004; Zhang et al. 2007; Xu et al. 2010; Tybura et al. 2012).

Since the results on the possible relationship between DRD2 and DAT1 genetic variants with treatment response are still inconsistent (Yoshida & Muller 2018), and patients included in previous studies were not separated by gender (Sagud et al. 2018), and were treated with different antipsychotic drugs, this pharmacogenetic study, with a longitudinal design, aimed to evaluate the association between genetic variants of the DRD2 rs1800497 and DAT1 rs28363170 with symptomatic remission in Croatian male patients with schizophrenia. Remission was determined according to the “Remission in Schizophrenia Working Group”/RSWG/ criteria (Andreasen et al. 2005) to 6-months monotherapy with olanzapine. The hypothesis of the study was that particular genetic variants of the DRD2 rs1800497 and DAT1 rs28363170 will be associated with olanzapine-induced remission in schizophrenia.

**SUBJECTS AND METHODS**

**Sample**

The present study included 150 male patients with schizophrenia and was carried out at the Neuropsychiatric Hospital Dr. Ivan Barbot, Popovaca, Croatia, and at the University Hospital Centre Zagreb, Zagreb, Croatia. Inclusion criteria were: male patients, age range 19 to 60 years (median 33, IQR 28-42), body mass index (BMI) < 30 (median 25.7, IQR 23.1-28.5), DSM-IV diagnosis of schizophrenia, monotherapy with olanzapine, acute exacerbation of schizophrenia, and Caucasian ethnicity living in Croatia. Exclusion criteria were: serious somatic illnesses, neurologic disorders, previous therapy with clozapine and electroconvulsive therapy, and a history of drug use during the previous 6 months. The study was approved by the Ethics Committee of the Neuropsychiatric Hospital Dr. Ivan Barbot (Popovaca, Croatia) and the Zagreb School of Medicine (Zagreb, Croatia). All subjects provided written informed consent with the committee’s guidelines. Therefore, all human studies have been approved by the corresponding Ethics Committees, confirming the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000).

**Genotyping of the DRD2 rs1800497 and DAT rs28363170**

Genomic DNA was extracted from peripheral blood (5-10 ml) using standard salting-out method (Miller et al. 1988). Genotyping for DRD2 Taq1ARFLP (rs1800497) was performed by polymerase chain reaction (PCR) - restriction fragment length polymorphism (RFLP) methods. The 6 alleles of the VNTR polymorphism in DAT1 (rs28363170), consisting of 6, 7, 8, 9, 10, or 11 copies of the 40-base-pair repeat sequence were determined.

**Psychiatric evaluation**

The study was conducted between April 2008 and May 2011. Participants were evaluated two times with the Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987) during the first day of admission, and after 6 months, by psychiatrists with extensive clinical experience. Raters were blind to DRD2 rs1800497 and DAT1 rs28363170 genotypes of patients. Most of the patients were taking atypical antipsychotics (except clozapine) before the inclusion in the protocol (89.3%), whereas a smaller number of patients was drug-na"ive (10.7%). However, prior to study (4-6 months), 118 patients (78.7%) did not take any medication, while 32 patients (21.3%) were on different medications. Since all patients were in the exacerbation, no wash out was performed. All patients received olanzapine monotherapy (5-20 mg/d). Only one brand of olanzapine was used throughout the trial to ensure bio-availability. After titration of the dose of olanzapine during the first few days of admission (7±2 days), participants remained at a fixed dose of olanzapine to the end of the study. During the study no concomitant medication was allowed except benzodiazepines for insomnia and anxiety. Patients were excluded from the study in case of correction of the dose of olanzapine or switching to another antipsychotic. Treatment response was defined according to the remission criteria by the RSWG, consisting of a reduction to mild levels on the key 8 symptoms on the PANSS scale (items P1, P2, P3, N1, N4, N6, G5, G9) for at least 6 months (Andreasen et al. 2005). Patients were divided into two groups, remitted and non-remitted, depending whether they meet the remission (RSWG) criteria.
Statistical analysis

All confidence intervals were given at the 95% level. Normality of distribution of continuous variables, like age, BMI, or PANSS score, was tested by Kolmogorov-Smirnov test for samples greater than 30, or by Shapiro-Wilk test for samples smaller than 30. Median and interquartile range were used as measures of central tendency and variability when distribution did not significantly deviate from the normal one. Homogeneities of variances of continuous variables were tested by Levene test. Differences in mean values for the continuous, numeric variables between more than two categories of a nominal variable were analyzed by ANOVA, if distribution did not significantly deviate from the normal one, and if variances were homogenous. Standard measure of effect size given with ANOVA was $\eta^2$. To analyze which of two genotype/allele groups differ significantly, Bonferroni post hoc test was used. Univariate and multivariate prediction of symptomatic remission were carried by means of logistic regression and odds ratios with 95% confidence intervals given for each variable. Genotype or allelic frequencies between remitted and non-remitted patients and Hardy-Weinberg equilibrium (HWE) were evaluated using Pearson’s $\chi^2$ test and Yates correction for continuity. To test the possibility of gene-gene interaction, a series of hierarchical multivariate prediction of remission was made. In each analysis, all the polymorphisms were entered in analysis at first step, then the product of two polymorphisms was added, and we tested statistical significance of its contribution to predict remission. Procedure was repeated for all possible 2- and 3-way interactions. All the analyses were carried out Sigma Stat 3.5 (Jandel Scientific Corp. San Rafael, CA, USA).

Due to multiple comparisons (testing the association of 2 polymorphisms), a correction was performed and p value was set to $p=0.05/2=0.025$. G*Power 3 Software (Faul et al. 2007) was used to determine the required sample size and statistical power. For multiple regression, with $p=0.025$; median effect size $=0.15$; and power $(1-\beta)=0.800$; number of predictors= 2; the required sample size was 66. For the Mann-Whitney test, with $p=0.025$; median effect size $=0.5$; and power $(1-\beta)=0.800$; the required sample size was 128. For $\chi^2$ test, with $p=0.025$; median effect size $=0.3$; and power $(1-\beta)=0.800$; the required sample size was 128.

As the study included 150 subjects at the beginning, and 145 subjects after 6 months, it had a needed sample size. Only for ANOVA, the study did not include enough subjects since with $p=0.025$; median effect size $=0.25$; and power $(1-\beta)=0.800$; the required sample size was 189. Therefore, the study, with corrected P value (0.025) and needed power of 0.800, had adequate sample size for the most of the comparisons, except ANOVA, to detect significant differences among the groups if they existed.

RESULTS

From 150 male patients with schizophrenia that were assessed initially, five dropped out during the study, and therefore the remaining 145 subjects were included in further analysis. Distribution of age and BMI values significantly deviated from normal distribution (age: Kolmogorov-Smirnov $z=0.098$; $p=0.001$, BMI: Kolmogorov-Smirnov $z=0.087$; $p=0.007$), and therefore median and interquartile range were used as measures of central tendency and variability (age: median 33; IQR 25.7; IQR 23.1-28.5).

Symptomatic remission was achieved in 45 patients (31%), according to proposed criteria in all 8 key items in the PANSS scale after six months (Table 1). It was not significantly related to smoking status since smokers and non-smokers had had similar odds (OR=1.6; 95% CI=0.74-3.36; univariate logistic regression) to achieve remission.

When analyzing differences in baseline PANSS scores between subjects who achieved symptomatic remission and those who did not achieve remission, a significant difference was found in the PANSS negative (Mann-Whitney U=1285.5; Z=-4.139, $p<0.001$; AUC=0.29), PANSS general psychopathology (Mann-Whitney U=1407.5; Z=-3.604, $p<0.001$; AUC=0.31) and PANSS total (Mann-Whitney U=1427; Z=-3.519, $p<0.001$; AUC=0.33) scores. Namely, all patients that achieved symptomatic remission had lower values in PANSS total scores, and PANSS negative and general psychopathology subscales at baseline than patients who did not achieve remission (Table 2).

Table 1. Results of symptomatic remission according to proposed criteria (8 items of PANSS<3 during 6 months follow up, n=150) in male patients with schizophrenia treated for 6 months with olanzapine monotherapy

| Remission criteria | N=150 | % |
|--------------------|-------|---|
| Remission after 6 months treating with olanzapine | 45 | 31.0 |
| remission | 100 | 69.0 |
| no remission | 145 | 100 |
| total | | |
| Remission criteria | 45 | 30.0 |
| remission (at all 8 items result <3) | 80 | 53.3 |
| no remission (items >3) | 18 | 12.0 |
| positive response, but less than 6 months | 2 | 1.3 |
| positive response, but deteriorated after 6 weeks; added another antipsychotic | 5 | 3.3 |

N = number of subjects; % = percent of subjects; PANSS = Positive and Negative Syndrome Scale
DRD2 rs1800497 and DAT1 rs28363170 genotypes did not deviate from the HWE (Pearson’s $\chi^2$ test). Symptomatic remission was evaluated in patients with schizophrenia subdivided according to the DRD2 and DAT genotypes (Table 3) and alleles (Table 4). DRD2 rs1800497 and DAT1 rs28363170 genotypes or alleles were not significantly associated ($P > 0.025$) with symptomatic remission (univariate logistic regression analysis).

To further assess this lack of association, the frequency of the DRD2 rs1800497 and DAT1 rs28363170 genotypes and alleles was evaluated in subjects with or without symptomatic remission. No significant differences in the distribution of the DRD2 rs1800497 ($\chi^2 = 2.702; \text{df}=2; P=0.259$) or DAT1 rs28363170 genotypes, or DRD2 rs1800497 ($\chi^2 = 1.361; \text{df}=1; P=0.243$) or DAT1 rs28363170 ($\chi^2 = 0.575; \text{df}=1; P=0.448$) alleles were detected between patients with or without symptomatic remission, respectively.

In addition, no significant enhancement to the prediction of symptomatic remission was shown when the interaction of DRD2 rs1800497 and DAT1 rs28363170 ($\chi^2 = 2.76; P=0.598$) was tested.

The PANSS total, positive, negative and general psychopathology scores, corrected by smoking status (ANOVA), did not differ significantly ($P > 0.025$) after 6 months of olanzapine treatment in 45 patients with symptomatic remission, subdivided into carriers of the DRD2 and DAT1 genotypes (Table 5). Accordingly, no significant ($P > 0.025$) changes (Mann-Whitney U test) were found in the total, positive, negative and general psychopathology PANSS scores after 6 months of olanzapine treatment in 45 patients with symptomatic remission, after they were subdivided into carriers of the DRD2 and DAT1 alleles (Table 6).

### Table 2. Symptomatic remission in male patients with schizophrenia in relation to PANSS scores at baseline assessment

| PANSS subscale scores | Remission achieved | Remission not achieved | $P$ | Effect |
|-----------------------|--------------------|------------------------|-----|--------|
|                       | Median | IQR      | Median | IQR      |       |        |
| Positive symptoms     | 37    | 32-40    | 36   | 32-39    | 0.646 |        |
| Negative symptoms     | 34    | 29-35    | 36   | 34-39    | <0.001| 0.29   |
| General psychopathology | 59   | 54-63    | 63   | 59-69    | <0.001| 0.31   |
| PANSS total score     | 127   | 119-135  | 136.5| 126.5-142.8| 0.001| 0.32   |

IQR = interquartile range; $P$ = Mann-Whitney U test for two independent groups; effect = standardized measure of size effect for statistically significant results; PANSS = Positive and Negative Syndrome Scale.

### Table 3. Symptomatic remission in patients with schizophrenia subdivided according to the DRD2 rs1800497 and DAT1 rs28363170 genotypes

| Genotypes | Remission achieved | Remission not achieved | Total | $P$ | ORuv 95% CI |
|-----------|--------------------|------------------------|-------|-----|-------------|
| DRD2      |                    |                        |       |     |             |
| A1A2      | 11                 | 22.4                   | 38    | 77.6| 49          | 100.0 | 1          |
| A2A2      | 31                 | 36.0                   | 55    | 64.0| 86          | 100.0 | 0.104      | 2.0  | 0.87-4.34 |
| A1A1      | 3                  | 30.0                   | 7     | 70.0| 10          | 100.0 | 0.610      | 1.5  | 0.33-6.70 |
| DAT       |                    |                        |       |     |             |
| 9/10      | 17                 | 27.0                   | 46    | 73.0| 63          | 100.0 | 1          |
| 10/10     | 24                 | 33.8                   | 47    | 66.2| 71          | 100.0 | 0.393      | 1.4  | 0.66-2.90 |
| 9/9       | 3                  | 33.3                   | 6     | 66.7| 9           | 100.0 | 0.692      | 1.4  | 0.30-6.02 |

OR = odds ratio; 95% CI = 95% confidence interval for odds ratio; uv = univariate logistic regression; DRD2 = dopaminergic receptor type 2; DAT: dopaminergic transporter.

### Table 4. Symptomatic remission in patients with schizophrenia subdivided according to the DRD2 rs1800497 and DAT1 rs28363170 alleles

| Alleles | Remission achieved | Remission not achieved | P | ORuv 95% CI |
|---------|--------------------|------------------------|   |            |
| DRD2    |                    |                        |   |            |
| A2A2    | 73                 | 81.1                   | 148 | 74.0 | 0.191      | 1.50  | 0.92-2.79 |
| A1A1    | 17                 | 18.9                   | 52  | 26.0 | 0.019      | 1.50  | 0.92-2.79 |
| DAT     |                    |                        |   |            |
| 10/10   | 65                 | 73.9                   | 140 | 26.1 | 0.019      | 1.50  | 0.92-2.79 |
| 9/9     | 23                 | 26.1                   | 64  | 73.9 | 0.019      | 1.50  | 0.92-2.79 |

OR = odds ratio; 95% CI = 95% confidence interval for odds ratio; uv = univariate logistic regression; DRD2 = dopaminergic receptor type 2; DAT: dopaminergic transporter.
Table 5. Differences in total, positive, negative and general psychopathology PANSS scores after 6 months of olanzapine treatment in 45 patients with symptomatic remission subdivided according to the DRD2 rs1800497 and DAT1 rs28363170 genotypes

| Genotypes | N     | PANSS total Mean | SD    | P     | PANSS positive Mean | SD    | P     | PANSS negative Mean | SD    | P     | PANSS general Mean | SD    | P     |
|-----------|-------|-----------------|-------|-------|---------------------|-------|-------|---------------------|-------|-------|-------------------|-------|-------|
| DRD2      |       |                 |       |       |                     |       |       |                     |       |       |                   |       |       |
| A2A2      | 31    | 51.61           | 12.48 | 0.976 | 11.03               | 3.47  | 0.934 | 15.58               | 4.13  | 0.967 | 25.00             | 6.26  | 0.970 |
| A2A1      | 11    | 52.00           | 10.19 |       | 11.27               | 2.37  |       | 15.55               | 3.86  |       | 25.18             | 5.55  |       |
| A1A1      | 3     | 52.33           | 17.21 |       | 12.00               | 5.00  |       | 15.00               | 5.29  |       | 25.33             | 7.23  |       |
| DAT       |       |                 |       |       |                     |       |       |                     |       |       |                   |       |       |
| 10/10     | 24    | 51.04           | 12.04 | 0.158 | 10.71               | 3.08  | 0.311 | 15.38               | 4.30  | 0.140 | 24.96             | 5.92  | 0.410 |
| 9/10      | 17    | 55.18           | 11.48 |       | 12.18               | 3.54  |       | 16.59               | 3.46  |       | 26.41             | 6.10  |       |
| 9/9       | 3     | 44.67           | 7.37  |       | 10.33               | 2.08  |       | 13.33               | 2.08  |       | 21.00             | 4.58  |       |

P = ANOVA for more than two independent groups; PANSS = Positive and Negative Syndrome Scale; DRD2 = dopaminergic receptor type 2; DAT = dopaminergic transporter

Table 6. Differences in total, positive, negative and general psychopathology PANSS scores after 6 months of olanzapine treatment in 45 patients with symptomatic remission according to DRD2 rs1800497 and DAT1 rs28363170 alleles

| Alleles | N     | PANSS total Median | IQR  | P     | PANSS positive Median | IQR  | P     | PANSS negative Median | IQR  | P     | PANSS general Median | IQR  | P     |
|---------|-------|--------------------|------|-------|-----------------------|------|-------|-----------------------|------|-------|----------------------|------|-------|
| DRD2    |       |                    |      |       |                       |      |       |                       |      |       |                     |      |       |
| A2      | 73    | 49                 | 43-62| 0.853 | 11                   | 8-14 | 0.582 | 15                   | 13-19| 0.844 | 23                 | 21-30| 0.885 |
| A1      | 17    | 54                 | 43-61|       | 11                   | 8-14 |       | 15                   | 14-19|       | 25                 | 20-30|       |
| DAT     |       |                    |      |       |                       |      |       |                       |      |       |                     |      |       |
| 10      | 65    | 49                 | 44-62| 0.712 | 11                   | 8-14 | 0.835 | 16                   | 13-19| 0.447 | 24                 | 22-30| 0.458 |
| 9       | 25    | 49                 | 42-59|       | 11                   | 8-14 |       | 15                   | 13-19|       | 24                 | 19-20|       |

P = Mann-Whitney U test for two groups; PANSS = Positive and Negative Syndrome Scale; DRD2 = dopaminergic receptor type 2; DAT = dopaminergic transporter

DISCUSSION

Present study is the first to simultaneously evaluate the association between DRD2 rs1800497 and DAT1 rs28363170 gene variants and symptomatic remission after 6-months olanzapine monotherapy in male Caucasian patients with schizophrenia. Our results revealed that DRD2 rs1800497 and DAT1 rs28363170 genetic variants are not associated with symptomatic remission, either alone, or in interaction with each other. These genetic variants were also not related to symptoms evaluated by the PANSS. Therefore, DRD2 rs1800497 and DAT1 rs28363170 variants might not be used to predict the response to 6 months of monotherapy with olanzapine in male schizophrenic patients.

Non-response to treatment is frequent in schizophrenia (Lally et al. 2016). The proportion of responders varies between studies (Thomas et al. 2008, Novick et al. 2007, Levine et al. 2012). Large number of non-genetic confounding factors, like diagnosis, illness course, anti-psychotic drugs prescribed, treatment duration and adherence, assessment of efficacy and adverse effects, concordant medication and co-morbidities, can affect individual response (Arranz et al. 2011). In line with previous data (Levine et al. 2012, Terzic et al. 2016), 31% of participants in our study achieved symptomatic remission. Remission was not influenced by smoking. In the recent systematic review, patients with multiple episodes had remission rates between 16% and 62%, with a weighted mean of 37% (AlAqeel & Margolese 2012), which is higher than in our patients. Therefore, this difference might be induced by chronicity and/or previous pharmacological treatment. Namely, longer treatment duration, higher number of hospitalizations and longer illness course (van Haren et al. 2007, Levine et al. 2012), different definitions and different criteria of symptomatic remission (Andreasen et al. 2005, Lieberman et al. 2003), different duration of the study period, high dropout rates, variations in sample selection (Lambert et al. 2010, AlAqeel & Margolese 2012) might influence treatment outcome. Present study applied RSWG criteria (Andreasen et al. 2005) with lower stringency (low threshold of the 8 core PANSS symptoms) and longer time (6 months) criterion, that contain positive and negative symptoms, core dimensions of schizophrenia (Cassidy et al. 2010). Our patients, who have achieved symptomatic remission, had lower values in PANSS negative, general psychopathology and PANSS total scores at baseline. This suggests that increased severity of symptoms, except on the PANSS positive subscale, is associated with lower chance to achieve symptomatic remission. Reduced baseline illness severity is one of the most relevant predictors of the symptomatic remission (AlAqeel & Margolese 2012). Another less clear predictor is male gender, since female gender was a predictor of remission (Anderson et al. 2017, Mihaljevic Peles et al. 2016). In our study middle-aged male patients with multiple episodes displayed low remission frequency (31%) during 6 months' follow-up, which was similar to 32% remission found in Slovenian patients with schizophrenia (Terzic et al. 2016).
In our study DRD2 rs1800497 was not associated with symptomatic remission after 6 months of monotherapy with olanzapine in male schizophrenic patients. Variations in the DRD2 gene have been investigated in relation to treatment response (Yoshida & Müller 2018, Kaur et al. 2017, Teržić et al. 2016, Huang et al. 2016a,b, Zhang et al. 2015, Kang et al. 2015, Blasi et al. 2015), but not remission, and there are no data related to olanzapine monotherapy. Significant association between three SNPs on DRD2 gene (rs180498, rs2514218 and rs1079597) and antipsychotic treatment response was reported (Kaur et al. 2017, Zhang et al. 2015, Huang et al. 2016a,b, Kang et al. 2015). Other polymorphism, DRD2 rs1799732 (-141C Ins/Del), was not related to treatment response (Teržić et al. 2016, Bishop et al. 2015). In line with no relationship between the rs1800497 polymorphism and response to different antipsychotics (Zhang et al. 2011, Kang et al. 2015, Escamilla et al. 2018), the results of the present study revealed no association between DRD2 rs1800497 and symptomatic remission, or symptoms of schizophrenia, in male schizophrenic patients treated for 6 months with olanzapine monotherapy. Previous studies that included treatment with various typical and atypical antipsychotics revealed inconsistent findings (Aleinis et al. 2008, Shen et al. 2008, Tybura et al. 2012, Vehof et al. 2012). The lack of association between symptomatic remission to olanzapine and DRD2 rs1800497 was confirmed in other studies showing that DRD2 rs1800497 was not related to the response to different antipsychotics (Escamilla et al. 2018), such as amisulpride (Kang et al. 2015), perazine, olanzapine or ziprasidone (Tybura et al. 2012).

In agreement with previously published studies (Zhang et al. 2007, Xu et al. 2010, Tybura et al. 2012) and results from different Croatian patients (Bilić et al. 2014), no significant association was detected between DAT1 rs28363170 and symptomatic remission to olanzapine, or with PANSS scores in remitted patients. Negative findings might be explained by the different DAT tissue distribution (Piccini 2003). However, the DAT density was not affected by olanzapine (Kim et al. 2006) or by other antipsychotics or illness duration (Fusar-Poli & Meyer-Lindenberg 2013). Furthermore, negative findings might be due to the interactive effects of DAT1 rs28363170 with other DAT polymorphisms or with other dopaminergic gene polymorphisms, that could influence transcription and stability of mRNA or translational efficiency (Heinz et al. 2000). The interaction with DRD2 rs1800497 was not confirmed in the present study. DAT1 rs28363170 might interact with other gene polymorphisms such as serotonin transporter polymorphism (5HTTLPR), since schizophrenic patients, carriers of the DAT 10/10 or 10/12 genotypes and S carriers of the 5HTTLPR, were more likely to be treatment resistant compared to L carriers (Bilić et al. 2014). Besides differences in the treatment response and remission, as we did not evaluate 5HTTLPR gene variants in this study, we cannot confirm these findings.

The limitations of the study should be acknowledged: a relatively small sample size of patients with schizophrenia (N=150), especially in a group with symptomatic remission (N=45). However, RSWG criteria (Andreasen et al. 2005) of 6 months’ duration might explain this low rate of remission. To overcome this limitation, we corrected p value to 0.025, and calculated in advance the needed sample size and statistical power: for power of 0.800, and expected moderate effect sizes, the study had moderate but adequate sample sizes for most of the comparisons; however, the results were negative. In addition, previously published studies evaluating olanzapine response were conducted using smaller samples, including both genders (Thomas et al. 2008). Only two dopaminergic polymorphisms were analyzed, and plasma concentration of olanzapine was not determined. The concentration-dependent therapeutic failures between studies might be explained by the large inter-individual variation in the pharmacogenetics of olanzapine.

Strengths of the present study include olanzapine monotherapy, inclusion of ethnically homogenous Caucasian patients with schizophrenia, only male subjects, usage of RSWG criteria and the longitudinal study design of 6 months follow up, which is well suited and powerful to address issues related to treatment response. Divergent pharmacogenetic results could be explained by the varieties in the study designs, small sample sizes, ethnic differences in the frequency of studied genotypes, small effect sizes of most genetic variants, uncompleted coverage of the most genes, lack of control of environmental and clinical confounders, differences in definition of outcome parameters, or insufficient incorporation of gene-gene and gene-environment interaction (Brandl et al. 2014, Yoshida & Müller 2018, Tunbridge et al. 2019). This longitudinal study tried to control for most of these confounders and reported negative findings.

CONCLUSION

In conclusion, the results of the present study revealed a lack of association between DRD2 rs1800497 and DAT1 rs28363170 genetic variants and symptomatic remission and/or symptoms of schizophrenia in male patients treated for 6 months with olanzapine monotherapy. Our previous study reported that COMT rs4680 was not significantly associated with symptomatic remission in male patients with schizophrenia treated with olanzapine monotherapy (Zivkovic et al. 2019). These data collectively suggest that these genetic variants of the dopaminergic system could not be used to predict remission after olanzapine monotherapy. However, negative results should be either rejected or confirmed in the larger samples (Tunbridge et al. 2019), including haplotype analyses (Sagud et al. 2018), to detect clinically useful and easy obtainable pharmacogenetic markers that might predict therapeutic response or remission in schizophrenia.
Acknowledgements:
This study was supported by the Croatian Ministry of Science, Education and Sport (grants 108-1083509-3513, 098-0982522-2455; and 098-0982522-2457), but it has no involvement in study design; in the collection, analysis and interpretation of data. Part of the statistical analysis was carried out by Biometrika Healthcare Research, Croatia. All authors contributed to and have approved the final manuscript.

Conflict of interest: None to declare.

Contribution of individual authors:
Maja Zivkovic, Alma Mihaljevic-Peles & Dorotea Muck-Seler were responsible for the idea and design of the study.

Maja Zivkovic & Nela Pivac were involved in the interpretation of findings and prepared the first draft of the manuscript.

Nela Pivac wrote the final draft of the manuscript.

Maja Zivkovic, Alma Mihaljevic-Peles, Marina Sagud & Suzana Vlatkovic were responsible for collection of data, explained the research goals and described protocol in details to the patients; explained the inclusion/exclusion criteria, insured participant adherence for the participation in the study, motivated, selected, diagnosed, evaluated and sampled patients and did psychiatric diagnoses and evaluation of the remission.

Lucija Tudor did the statistical analyses.

All authors have read and approved the final version and have contributed substantially to the design, performance, analysis, and reporting of this study.

References
1. Al Aqeel B & Margolese HC: Remission in schizophrenia: critical and systematic review. Harv Rev Psychiatry 2012; 20:281-97
2. Allenius M, Wandelius M, Doh, ML, Hartvig P, Lindstrom L & Hammarsland-Udenaes M: Gene polymorphism influencing treatment response in psychotic patients in naturalistic setting. J Psychiatr Res 2008; 42:884-93
3. Anderson JP, Icten Z, Alas V, Benson C & Joshi K: Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 2017; 17:346
4. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR & Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiat 2005; 162:441-9
5. Arranz MJ, Rivera M & Munro JC: Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011; 25:933-69
6. Blic P, Jakic V, Vilbic M, Savic A & Bozina N: Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene 2014; 543:125-32
7. Bishop JR, Reilly JL, Harris MSH, Patel SR, Kittles R, Badner JA, et al: Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology (Berl) 2015; 232:145-54
8. Blasi G, Selvaggi P, Fazio L, Antonucci LA, Taurisano P, Masellis R, et al: Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics. Neuropsychopharmacology 2015; 40:1600-8
9. Brandl EJ, Kennedy JL, & Muler DJ: Pharmacogenetics of antipsychotics. Can J Psychiatry 2014; 59:76-88
10. Cassidy CM, Norman R, Manchanda R, Schmitz N & Malla A: Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull 2010; 36:1001-8
11. Escamilla R, Camarena B, Saracco-Alvarez R, Fresán A, Hernández S & Aguilar-García A: Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatric Dis Treat 2018; 14:2981-7
12. Fauf F, Erdfeider E, Lang AG & Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39:175-91
13. Fusar-Poli P & Meyer-Lindenberg A: Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull 2013; 39:22-32
14. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22:133-9
15. Huang E, Maciukiewicz M, Zai CC, Tiwari AK, Li J, Potkin SG, et al: Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics 2016a; 17:103-9
16. Huang E, Zai CC, Lissovay A, Maciukiewicz M, Felsky D, Tiwari AK, et al: Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int J Neuropsychopharmacol 2016b; 19:pyv132
17. Ishigooka J: The characteristics and application of new antipsychotic drugs. JMAJ 2004; 47:270-5
18. Kang SG, Na KS, Lee HJ, Chee IS, Lee K, & Lee J: DRD2 genotype and haplotype variation is associated with improvements in negative symptoms after 6 weeks’ amisulpride treatment. J Clin Psychopharmacol 2015; 35:138-62
19. Kaur G, Gupta D, Chavan BS, Sinhmar V, Prasad R, Tripathi A, et al: Identification of genetic correlates of response to risperidone: findings of a multicentric schizophrenia study from India. Asian J Psychiatr 2017; 29:174-82
20. Kay SR, Fishein A & Opfer LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-76
21. Lally J, Gaughran F, Timms P & Curran SR: Treatment-resistant schizophrenia: current insights on the
pharmacogenomics of antipsychotics. Pharmacogenomics Pers Med 2016; 9:117-29
22. Lally J & MacCabe JH: Antipsychotic medication in schizophrenia: a review. Brit Med Bull 2015; 114:169-79
23. Lambert M, Karow A, Leucht S, Schimmelmann BG & Naber D: Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 2010;12: 393-407
24. Levine SZ, Rabionovitz J, Faries D, Lawson AH, & Ascher-Svanum H: Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012; 137:141-6
25. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al: Atypical and conventional antipsychotic drugs in treatment-refractory first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28:995-1003
26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23
27. Mi H, Thomas PD, Ring HZ, Jiang R, Sangkuhl K, Klein TE et al: PharmGKB summary: dopamine receptor D2. Pharmacogenet Genomics 2011; 21:350-369
28. Mihaljevic-Peles A, Sagud M, Filipic IS, Grosi, V, Pedisic I & Emsley R: Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatr Danub 2016: 28:263-72
29. Miller SA, Dykes DD & Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215
30. Novick D, Haro JM, Suarez D, Lambert M, Lepine JP & Naber D: Symptomatic remission in previously untreated patients with schizophrenia: 2 year results from the SOHO study. Psychopharmacology 2007; 191:1015-22
31. Piccini PP: Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; Suppl 7: S3-8
32. Sagud M, Tudor L, Nikolac Perkovic M, Uzun S, Zivkovic M, Konjevod M et al: Haplotypic and genotypic association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia. Front Pharmacol 2018; 9:705
33. Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ et al: Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2008; 43:600-6
34. Szekeres G, Keri S, Juhasz A, Rimánocy A, Szendi I, Czimmer C et al: Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124:1-5
35. Terzic T, Kastelic M, Dolzan V & Kores Plesevic B: Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia Psychiatr Danub 2016; 28:127-31
36. Thomas P, Srivastava V, Singh A, Mathur P, Ningaonkar VL, Lerer B et al: Correlates of response to olanzapine in the North Indian schizophrenia sample. Psychiatry Res 2008; 161:275-83
37. Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A & Harrison PJ: Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1-3, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol Psychiatry 2019; 86:608-20
38. Tybura P, Samochowiec A, Besleža A, Grzywacz A, Mak M, Frydecka D et al: Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol Rep 2012; 64:528-35
39. van Haren NE, Hulshoff Po, HE, Schnack HG, Cahn W, Brans R, Carati I et al: Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 2008; 63:106-13
40. Velhof J, Burger H, Wilfert B, Al Hadithy A, Alizadeh BZ, Sniedier H et al: Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol 2012; 22:625-31
41. Xu M, Xing Q, Li S, Zhong Y, Wu S, Gao R, et al: Pharmacogenetics effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1026-32
42. Yoshida K & Müller DJ: Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsycpharmacol 2018; 1:26
43. Zhang A, Xing Q, Wang L, Du J, Yu L, Lin Z et al: Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007; 8:1337-45
44. Zhang JP & Malhotra AK: Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7:9-37
45. Zhang JP, Robinson DG, Galleco JA, John M, Yu J, Addington J, et al: Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis. Schizophr Bull 2015; 41:1248-55
46. Zivkovic M, Mihaljevic-Peles A, Muck-Seler D, Sagud M, Ganoci L, Vlatkovic S et al: The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: a longitudinal study. Psychiatry Res 2019; 279:389-90

Correspondence:
Professor Nela Pivac, PhD
Rudjer Boskovic Institute
Bijenicka 54, 10 000 Zagreb, Croatia
E-mail: npivac@irb.hr